The major component of blood vessels is a single layer of endothelial cells and smooth muscle cells or mural cells. Secreted and membrane proteins expressed in endothelial cells and smooth muscle cells play particular roles in the physiology and pathophysiology of blood vessels. To identify secreted and membrane proteins expressed in endothelial cells, we performed signal sequence trap screening using a retrovirus-based expression cDNA library of human microvascular endothelial cells. One of the genes isolated encoded a novel putative secretory isoform of activated leukocyte cell adhesion molecule (ALCAM), 1 also known as BEN, SC1, DM-GRASP, MEMD, HCA, and CD166 (1) (2) (3) (4) (5) (6) .
ALCAM is a type I membrane protein that belongs to the Ig superfamily, and it has five extracellular variable type and constant type Ig domains and a single transmembrane domain. Human ALCAM was initially isolated as a ligand of CD6, a cell surface receptor belonging to the scavenger receptor cysteinerich protein superfamily (6) . CD6 is expressed on the surface of mature T cell and chronic B cell lymphocytic leukemia. Expression of CD6 on T cells is up-regulated following activation, and previous reports suggest that CD6 modulates T cell receptor signaling (7) . Therefore, binding of ALCAM to CD6 suggests that ALCAM may be involved in immune and/or inflammatory responses. In addition, ALCAM has been detected in a variety of cell types where it participates in heterophilic interactions with unknown ligands as well as homophilic interactions, suggesting that ALCAM has varied functions (8, 9) . In fact, BEN/ SC1/DM-GRASP, a chicken homologue of ALCAM, is expressed in the nervous systems and plays a role in axogenesis, neurite elongation, and synapse formation (2, 10, 11) . Although AL-CAM is expressed in a variety of cell types and tissues, it is certainly expressed in subsets of cells involved in dynamic growth and migration, including developing neuronal cells, hematopoietic cells. Although its physiological function is still unclear, its unique expression pattern suggests that ALCAM is involved in cell differentiation and migration.
Recently ALCAM expression has been detected in the fairly primitive subsets of hematopoietic cells and endothelial cells during embryogenesis (12) . ALCAM supports the development of hematopoietic progenitor cells and enhances the capillary tube formation of endothelial cells, suggesting that ALCAM is involved in both vasculogenesis and angiogenesis.
Here we isolated a novel soluble isoform of ALCAM (sAL-CAM) that is produced via alternative splicing. sALCAM demonstrated an ALCAM-independent effect in endothelial cell assays as well as a regulatory effect on ALCAM function. sAL-CAM mRNA expression is differentially regulated from that of ALCAM upon inflammatory stimulation. These data suggest * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. that sALCAM may modulate endothelial function through both ALCAM-dependent and ALCAM-independent pathways.
MATERIALS AND METHODS
Cloning of sALCAM-Signal sequence trap was performed as previously described (13) . Briefly, a library was constructed in the retrovirus vector pMX-SST employing cDNA derived from mRNA isolated from cultured human lung microvascular endothelial cells. The pMX-SST vector has a sequence encoding the constitutively active thrombopoietin receptor (MPL) downstream of the cloning site. When constitutive active MPL is expressed on the plasma membrane, it transmits a proliferative signal. The cDNA library was transfected into Phoenix-Eco packaging cells, and retroviruses carrying cDNA were collected. Interleukin-3 (IL-3)-dependent pro-B (Ba/F3) cells were infected with retrovirus followed by seeding on ten 96-multiwell plates (960 wells) in the absence of IL-3. Only Ba/F3 cells expressing the constitutively active MPL at the plasma membrane were able to grow in the absence of IL-3. IL-3-independent growth of Ba/F3 cells was observed in about 300 wells. Genomic DNA was extracted from these Ba/F3 clones, and PCR was performed using genomic DNA as a template and primers specific for the cloning vector. After electrophoresis of the PCR products, DNA was recovered and subjected to sequencing. Mouse sALCAM was identified through sequence data base searches (BC027280 and NT_096987.1 were used). The nucleotide sequence of the 3Ј-ends of human and mouse sALCAM was determined by 3Ј-rapid amplification cDNA ends using total RNA from human microvascular endothelial cells and the mouse endothelial cell line C166 cells, respectively.
Semiquantitative Reverse Transcription-PCR-Total RNA was extracted from cells using TRIzol (Invitrogen). cDNA was synthesized from 2.5 g of total RNA using the SuperScript first-strand synthesis system (Invitrogen). The forward primer 5Ј-GCTAGTAACTGAGGACAA-CGTG-3Ј and the reverse primer 5Ј-GAGCTTCTTATTCCTTCGGGCT-G-3Ј were used for ALCAM amplification. The forward primer 5Ј-ATAC-CTTGCCGACTTGACGTACCT-3Ј and the reverse primer 5Ј-AAAGAAC-ATGGTCTGGTACTGGCC-3Ј were used for sALCAM amplification. The forward primer 5Ј-CCTTCATTGACCTCAACTACATGG-3Ј and the reverse primer 5Ј-CCTGCTTCACCACCTTCTTGAT-3Ј were used for GAPDH amplification. PCR conditions were optimized so that quantification of amplified material was in the linear phase of amplification. After 3 min of incubation at 95°C, a PCR cycle of 95°C for 30 s, 58°C for 30 s and 72°C for 45 s was used. PCR cycles of 28 times, 30 times, and 26 times were performed for amplification of ALCAM, sALCAM, and GAPDH, respectively. The size of the PCR product was 543 bp, 340 bp, and 687 bp for ALCAM, sALCAM and GAPDH, respectively.
Purification of sALCAM and Western Blot Analysis-The coding region of human sALCAM was subcloned into the p3XFLAG-CMV-14 expression vector (Sigma) (sALCAM-p3XFLAG) and transfected into CHO cells using Lipofectamine 2000 (Invitrogen). 24 h after transfection, fresh growth media were provided, and cells were further incubated for 24 h. Finally, the media were collected and subjected to purification of sALCAM using the FLAG-M purification kit (Sigma). Protein concentration was measured by Bio-Rad protein assay (BioRad) based on the method of Bradford using bovine serum albumin as a standard. Protein generated in this fashion was employed for in vitro assays. For Western blot analysis, sALCAM-p3XFLAG was transfected into CHO cells in the same way, and cells were lysed in the CelLytic lysis reagent (Sigma). Cell lysate and conditioned culture media were incubated at 37°C for 3 h in the presence or absence of PNGase F (QA-Bio, San Mateo, CA) as recommended by the manufacturer. Western blot analysis was performed using anti-FLAG M2 antibody (Stratagene) as described previously (14) .
Cell Culture and Transfection-The embryonic yolk sac cell (Pro5) was cultured as described previously (15) . The coding region of human ALCAM was subcloned into pcDNA3 (Invitrogen) (ALCAM-pcDNA3) and transfected into Pro5 cells using Lipofectamine 2000. Independent clones of stable transfectants were selected in the presence of 1000 g/ml G418 (Pro 5/ALCAM). Mock transfectants were generated by transfection of empty pcDNA3 plasmid (Pro 5/MOCK). CHO cells were cultured as described previously (16) . Stable transfectants of ALCAM in CHO cells were generated as for the Pro5 cells (CHO/ALCAM and CHO/MOCK). Human lung microvascular endothelial cells (HMVEC) were obtained from Clonetics (San Diego, CA) and cultured on gelatincoated dishes. For stimulation experiments, HMVEC were cultured in EGM-2 MV media (Clonetics) until they became confluent and then incubated in the basal media without supplements for 24 h followed by stimulation with the indicated concentration of stimulant for the indicated time.
Wound-healing and Modified Boyden Chamber Assay-For the wound-healing assay, Pro5/MOCK and Pro5/ALCAM stable transfectants were grown to confluence in P60 dishes. A longitudinal scrape was made in the center of the dish with a pipette tip, and cells were then washed with phosphate-buffered saline. The initial images of cells were captured digitally, and thereafter cells were incubated in the media containing 5% fetal bovine serum in the presence or absence of 300 ng/ml sALCAM. After 24 h of incubation, images of cells were captured again, and the migration distance of the cells at the wound edge was measured for at least five points for each group. For the modified Boyden chamber assay, transwell inserts with 8-m pores for a 24-well plate (Costar, Acton, MA) were used. Membranes were placed into the lower chamber containing 250 l of migration buffer (Dulbecco's modified Eagle's medium with 1% bovine serum albumin). When HMVEC were used, membranes were coated with gelatin. 8 ϫ 10 4 cells were seeded on the upper chamber in 500 l of migration buffer in the presence or absence of sALCAM at the indicated concentration. For Pro5 cells migration, no chemoattractant was examined; for HMVEC migration 50 ng/ml vascular endothelial growth factor were used to induce migration. After 4 h of incubation, non-migratory cells on the top chamber were scraped off with cotton swabs, and migratory cells on the bottom surface were fixed with methanol followed by staining with hematoxylin. Membranes were cut off from the top chamber and mounted onto slide glass, and migratory cells were counted under a microscope in at least five independent fields.
In Vitro Two-dimensional Tube Formation Assay on Matrigel-In vitro angiogenesis assays on Matrigel (BD Biosciences) were performed in 24-well plates coated with 200 l of Matrigel. 5 ϫ 10 4 Pro5 cells were plated on Matrigel in growth media in the presence or absence of 300 ng/ml sALCAM and incubated for 24 h. 1 ϫ 10 5 human microvascular endothelial cells were plated on Matrigel in the presence or absence of 500 ng/ml sALCAM and incubated for 15 h. Tube lengths in each group were measured in four independent fields.
sALCAM Binding Assay-The cording region of human ALCAM and nucleotides encoding a myc tag at its 3Ј-end was subcloned into a pME-18Sf expression vector that possesses the SR␣ viral promotor (16) (ALCAM-myc-pME). ALCAM-myc-pME or empty pME vector was transfected into COS-7 cells using Lipofectamine 2000 (Invitrogen). 24 h after transfection, cells were incubated with 1 or 10 g/ml sAL-CAM in the fresh culture media at 37°C for 30 min. Cells were rinsed with warmed culture media three times and then lysed in the CelLytic lysis reagent (Sigma). After the measurement of protein concentration, 30 g of each cell lysate was subjected to Western blot analysis.
Cell Aggregation Assay-Cell aggregation assay was performed as described previously (17) . Briefly, detached CHO/MOCK and CHO/ ALCAM cells were washed with Ca 2ϩ -free Hanks' balanced salt solution twice and cells were suspended in Ca 2ϩ -free Hanks' balanced salt solution containing 2% dialyzed fetal bovine serum (Invitrogen) to a final concentration of 2 ϫ 10 6 cells/ml. Cell suspensions were incubated in the presence or absence of 1 or 10 g/ml sALCAM in 1.5 ml siliconized tubes with gentle rotation on the platform rotator for 30 -90 min at 37°C. Cells were evaluated on a hemocytometer, and the aggregates consisting of more than three cells were counted.
Statistics-Differences between groups were analyzed using Student's t test; p Ͻ 0.05 was considered significant. All data are presented as mean Ϯ S.E. as indicated.
RESULTS
Isolation of Soluble ALCAM-Because secreted and membrane proteins play crucial roles in endothelial cell physiology, we employed the method of signal sequence trap using mRNA from HMVEC to isolate genes encoding such proteins. We obtained several novel genes, and one of them demonstrated high similarity to ALCAM. The nucleotide sequence of the coding region was identical to human ALCAM within the first 394 nucleotides, but then the sequence homology ended. Interestingly, immediately after the 394th nucleotide, an in-frame stop codon was identified such that this clone encoded a truncated form of ALCAM. This truncated protein would have 133 amino acids identical to amino-terminal ALCAM except two carboxyl-terminal amino acids and be comprised of a variable type immunoglobulin (Ig) domain alone (Fig. 1A) . Because there was no encoded transmembrane domain in this form of ALCAM, we named it soluble ALCAM (sALCAM). We also identified several cDNA sequences in the GenBank TM data base (BC057809, BC041127, and BU952023) that could encode sALCAM, supporting our findings.
Analysis of the genomic structure of human and mouse AL-CAM loci suggested that sALCAM mRNA is produced from the same gene via alternative splicing (Fig. 1B) . To determine the 3Ј-end of sALCAM, we performed 3Ј-rapid amplification cDNA ends using total RNA from human and mouse endothelial cells. Both human and mouse sALCAM transcripts were found to end in exon 3 (intron 2 for ALCAM), and the polyadenylation signal AATAAA was observed near the 3Ј-ends of both human (Fig.  1C ) and mouse (data not shown) sALCAM transcripts.
Expression of sALCAM-We examined the cell specificity of human ALCAM and sALCAM expression using semiquantitative PCR. Both ALCAM and sALCAM were expressed in a variety of cultured human cells, including endothelial cells and smooth muscle cells (Fig. 2A) . Given that more PCR cycles were required to obtain detectable levels of sALCAM DNA than were required for ALCAM, it is likely that ALCAM is expressed at higher levels than sALCAM in all cell types examined. Then we further examined their regulated expression upon stimulation of HMVEC. With stimulation by inflammatory regulators, AL-CAM and sALCAM expression was measured at 4, 12, and 24 h after stimulation. TNF-␣ was the only regulator that increased ALCAM expression and was noted after 4 h. However its effect was not observed at 12 and 24 h. On the other hand, sALCAM expression was moderately up-regulated with TNF-␣ treatment after 4 h, and its effect persisted even after 24 h. Phorbol 12-myristate 13-acetate (PMA) stimulation decreased expression of both ALCAM and sALCAM after 24 h, whereas vascular endothelial growth factor treatment did not show a significant effect. These data suggest that the mechanism for producing two alternative transcripts may be regulated (Fig. 2B) . . B, HMVEC were stimulated with 50 ng/ml vascular endothelial growth factor, 10 units/ml IL-1␤, 50 ng/ml lipopolysaccharide, 10 ng/ml TNF-␣, and 50 ng/ml PMA for 4 -24 h. Then semiquantitative reverse transcription-PCR of ALCAM, sAL-CAM, and GAPDH was performed. Three independent dishes of cells were assigned to each group. Values (mean Ϯ S.E.) are presented as a relative density corrected by GAPDH to control (p ϭ 1.00). TNF-␣ significantly increased sALCAM expression in a sustained fashion, whereas it slightly increased ALCAM expression only after 4 h. PMA decreased both AL-CAM and sALCAM expression in HM-VEC after 24 h.
Then we investigated whether sALCAM is a secreted protein. For this purpose, recombinant sALCAM was expressed in CHO cells by transient transfection. A FLAG epitope tag was added at carboxyl-terminal for the detection of recombinant protein. sALCAM was detected in the conditioned culture media as well as cell lysate, indicating that sALCAM is secreted (Fig. 3A) . The molecular weight of sALCAM in the media was different from sALCAM in the cell lysate, both of which were larger than the predicted molecular weight. Because sALCAM is predicted to have two N-linked glycosylation sites, we speculated that sALCAM undergoes post-translational modification. Therefore, we treated the cell lysate and the conditioned media with an endoglycosidase, PNGase F. After the deglycosylation, sALCAM in both cell lysate and media showed the same reduced molecular weight by Western blot analysis, indicating that sALCAM is glycosylated (Fig. 3A) . For further studies, we purified FLAG-tagged sALCAM protein from cell culture media, and the purity was confirmed by Coomassie Brilliant Blue staining (Fig. 3B) .
sALCAM Modulates Endothelial Cell Function-To examine the functions of ALCAM and sALCAM, we generated endothelial-like yolk sac cells (Pro5) stably expressing ALCAM. Pro5 cells did not express endogenous ALCAM (data not shown). We examined the role of ALCAM and sALCAM in migration with wound-healing and modified Boyden chamber assays. Because ALCAM expression is usually restricted to subsets of cells involved in dynamic growth and/or migration, including neural development, branching organ development, hematopoiesis, immune response, and tumor progression, we expected AL-CAM to enhance cell migration (9) . However, Pro5 cells expressing ALCAM (Pro5/ALCAM) showed less migration than mock-transfected control cells (Pro5/MOCK) by both assays (Fig. 4, A and B) . Interestingly, addition of sALCAM increased cell migration not only of Pro5/ALCAM but also of Pro5/MOCK, suggesting that sALCAM has an ALCAMindependent effect on cell migration (Fig. 4B) . Notably, 200 ng/ml sALCAM showed a maximum effect on Pro5/MOCK migration, whereas 1000 ng/ml sALCAM demonstrated a maximum effect on Pro5/ALCAM migration. Moreover, with 1000 ng/ml sALCAM, there was no significant difference of migration between Pro5/MOCK and Pro5/ALCAM, suggesting that at this concentration sALCAM could inhibit the ALCAM-dependent inhibitory effect on cell migration. The ALCAM-independent effect of sALCAM was not observed in the wound-healing assay, presumably because of greater variability in this assay compared with the Boyden chamber assay. We then examined ALCAM expressing cells in a tube formation assay on Matrigel. Pro5/ALCAM showed significantly enhanced tube formation compared with Pro5/MOCK. This enhancement of tube formation was also abolished by sALCAM (Fig. 4, C and D) .
Next we explored if sALCAM has a similar effect on human primary endothelial cells. We examined the migration and tube formation capacity of HMVEC, which highly express ALCAM, in the presence or absence of sALCAM. Similar to the results with Pro5/ALCAM, sALCAM enhanced HMVEC migration in a dose-dependent manner, and 1000 ng/ml sALCAM showed maximum effect (Fig. 5A) . sALCAM also inhibited tube formation of HMVEC on Matrigel (Fig. 5, B and C) . These data suggest that native ALCAM also has a primary inhibitory effect on endothelial cell migration but supports in vitro tube formation, and that sALCAM has an ability to modulate endothelial cell function.
sALCAM Has a Regulatory Effect on ALCAM Function-To explore whether sALCAM has an ability to bind ALCAM, we prepared COS cells expressing recombinant ALCAM-myc and incubated the cells with sALCAM. Binding was detected by Western blot analysis. No binding of sALCAM was observed at 1 g/ml concentration. However, at 10 g/ml concentration significant binding of sALCAM was observed to COS/ALCAM compared with COS/MOCK cells, suggesting that sALCAM has an ability to bind ALCAM (Fig. 6A) . Then we examined cell aggregation assays using CHO cells stably expressing ALCAM (CHO/ALCAM). After 30 min of incubation, significant aggregations were observed in CHO/ALCAM, whereas almost no aggregation was observed in mock-transfected control cells (CHO/MOCK) (Fig. 6B) . When CHO/ALCAM cells were incubated with 10 g/ml sALCAM, there were significantly fewer cell aggregates than observed for the CHO/ALCAM cells, whereas 1 g/ml sALCAM did not affect the formation of the cell aggregions (Fig. 6, B and C) . These results suggest that sALCAM has a regulatory effect on ALCAM-ALCAM homophilic interaction. FIG. 3. sALCAM is a secreted glycoprotein. A, sALCAMp3XFLAG was transfected into CHO cells. 24 h after transfection, cells were given fresh growth media and further incubated for 24 h. Then conditioned culture media was collected, and cell lysate was prepared followed by incubation in the presence (F) or absence (Ϫ) of PNGaseF at 37°C for 3 h. Western blot analysis was performed using anti-FLAG M2 antibody. B, sALCAM secreted into cell culture media was purified using anti-FLAG M2-agarose affinity gel. Its purity was examined by Coomassie Brilliant Blue staining.
DISCUSSION
We have described the isolation and characterization of a novel soluble isoform of ALCAM. sALCAM has a single variable type Ig domain that is identical to the amino-terminal Ig domain of ALCAM. Because the amino-terminal Ig domain of ALCAM is the vital adhesive binding site for both ALCAM-ALCAM homophilic and ALCAM-CD6 heterophilic interactions, it was considered likely that sALCAM has a regulatory role in blocking native ALCAM function (7, 18 -20) . Studies reported here indicate that sALCAM modulates endothelial cell function presumably through both ALCAM-dependent and ALCAM-independent pathways and that its expression is differentially regulated upon inflammatory stimulation.
ALCAM is a member of the Ig superfamily and has two variable type Ig domains followed by three constant type Ig domains in its extracellular region. The extracellular domains, or ectodomains, of adhesion molecules are important for specific ligand binding and molecular communication with cell surface proteins and extracellular matrix. It has been reported that these ectodomains can be released from the cell largely by proteolytic cleavage to yield soluble cell adhesion molecules (sCAM) (21) . Although the actual physiological roles of sCAM still remain to be elucidated, their capacity to bind the ligands suggest that they could act either as carrier molecules or as molecular buffers that neutralize excess ligand (21) . Moreover, it has been reported that sCAM play particular roles in angiogenesis, cell migration, and tumor growth (21) (22) (23) (24) (25) . Although proteolytic cleavage is the most common mechanism for the formation of sCAM, some are produced by alternative splicing such as that seen with PECAM and P-selectin (26 -28) . Both soluble PECAM and P-selectin are produced by skipping a single exon encoding a transmembrane domain. Therefore they contain the whole structure of extracellular domain. In contrast, although it is also produced via alternative splicing, sALCAM contains only a part of ectodomain of membranebound ALCAM. Furthermore, this is the first report that expression of a sCAM is differentially regulated from that of its membrane-bound counterpart.
TNF-␣ demonstrated moderate and persistent up-regulation of sALCAM expression in HMVEC, although it showed minimal early effect on ALCAM expression. Because TNF-␣ is a potent proinflammatory cytokine, sALCAM may play an important role in the response of endothelial cells to inflammation. ALCAM is a ligand for CD6 that is involved in T cell activation, and ALCAM expression is induced in T cells following activation (7). Moreover, much higher levels of ALCAM have been detected in monocyte lineage cells in synovial fluids of rheumatoid arthritis patient than those in resting monocytes (31) . These findings strongly suggest that ALCAM is involved in the pathophysiology of inflammation. Furthermore, we identified that ALCAM expression was up-regulated in the atherosclerotic aorta from apo-E knock-out mouse (data not shown). Given that inflammation plays crucial roles in atherosclerosis, ALCAM and sALCAM may play particular roles in the development of atherosclerosis (32) (33) (34) .
On the other hand PMA, a protein kinase C activator, reduced both ALCAM and sALCAM expression in HMVEC.
FIG. 6. sALCAM inhibits the ALCAM homophilic interaction.
A, COS cells expressing recombinant ALCAM-myc (COS/ALCAM-myc) and mock-transfected cells (COS/MOCK) were incubated with 1 g/ml or 10 g/ml sALCAM at 37°C for 30 min. After washing three times, cells were lysed, and 30 g of each lysate was subjected to Western blot analysis using anti-FLAG M2 antibody and anti-myc antibody. sAL-CAM protein was observed in association with COS/ALCAM-myc compared with COS/MOCK when 10 g/ml sALCAM was used. B, CHO cells expressing recombinant ALCAM (CHO/ALCAM) and mock-transfected cells (CHO/MOCK) were incubated in the presence or absence of 1 g/ml or 10 g/ml sALCAM, and formation of aggregations was observed. CHO/ALCAM formed distinct aggregations, whereas CHO/ MOCK did not. The addition of 10 g/ml sALCAM but not 1 g/ml sALCAM reduced the number and size of aggregates. C, the number of aggregates was scored under a microscope in nine independent fields. *, p Ͻ 0.0001 versus CHO/MOCK; **, p Ͻ 0.0001 versus CHO/ALCAM ϩ Vehicle; #, not significant versus CHO/ALCAM ϩ Vehicle. Lately, it has been reported that protein kinase C plays a dominant role in cytoskeleton-dependent ALCAM-mediated adhesion (35, 36) . PMA strongly reduced cytoskeleton-dependent ALCAM-mediated adhesion in myelomonocytic KG1 cells by reducing protein kinase C expression. However, PMA did not affect ALCAM expression in KG1 cells, indicating that reduction of ALCAM expression in HMVEC is a cell-specific effect of PMA. Because PMA is known to induce hyperpermeability in endothelial cells, reduction of ALCAM-mediated cell adhesion may contribute to PMA-induced hyperpermeability. Further experimental analysis is needed to elucidate the physiological meanings of ALCAM and sALCAM down-regulation by PMA.
Because ALCAM is expressed in highly motile cells such as extending neuronal cells, hematopoietic progenitor cells, and metastatic melanoma cells, we speculated that ALCAM might enhance cell motility (9) . However, Pro5/ALCAM showed less migratory capacity than Pro5/MOCK, indicating that ALCAM has an inhibitory effect on Pro5 migration. Addition of sAL-CAM increased cell migration of not only Pro5/ALCAM but also Pro5/MOCK, suggesting that sALCAM has an ALCAM-independent effect on cell motility. In the context of these findings, sALCAM enhanced the migration of primary human endothelial cells, HMVEC, in a dose-dependent manner. Notably, sAL-CAM showed maximum effect on cell migration of Pro5/AL-CAM and HMVEC at 1000 ng/ml, whereas 200 ng/ml sALCAM demonstrated the maximum effect for Pro5/MOCK. Given that with 1000 ng/ml sALCAM, Pro5/ALCAM showed similar mobility to Pro5/MOCK and HMVEC highly expressed ALCAM, 1000 ng/ml sALCAM could reverse the ALCAM-dependent inhibitory effect on cell migration. However, 10 g/ml sALCAM was required to observe the binding to ALCAM and the inhibitory effect on ALCAM-ALCAM homophilic interaction. Thus, we speculate that the ALCAM-dependent inhibitory effect on cell migration is mediated via ALCAM heterophilic interaction with an unknown ligand that could be inhibited by less sAL-CAM than that needed to inhibit ALCAM-ALCAM homophilic interactions. Further analysis is required to elucidate these issues.
Because it has been reported that ALCAM enhances the capillary tube formation of EOMA, a mouse endothelial cell line, we examined tube formation of Pro5/ALCAM on Matrigel (12) . Pro5/ALCAM demonstrated enhanced tube formation as compared with Pro5/MOCK, suggesting that ALCAM has a consistent acceleratory effect on capillary tube formation of endothelial cells regardless of endothelial cell type. sALCAM abrogated this effect of ALCAM on Pro5 tube formation and inhibited tube formation of HMVEC. These data indicate that sALCAM has an inhibitory effect on endothelial cell tube formation although it remains unclear whether this effect is achieved by inhibiting ALCAM function, by an ALCAM-independent effect of sALCAM, or through both types of pathways.
ALCAM is highly expressed in metastatic human melanoma cell lines (4) . It is also highly expressed in invasive vertical growth phase human melanoma whereas the majority of benign and thin melanoma do not express ALCAM (29) . Very recently, it has been reported that expression of recombinant amino-terminally truncated ALCAM (⌬N-ALCAM) diminished cell clustering mediated by wild-type ALCAM (30) . Furthermore, ⌬N-ALCAM promoted cell motility in vitro and increased invading and metastatic potential of melanoma cells. Therefore, ALCAM-mediated adhesion could represent a rate-limiting step in the transition from expansive primary tumor growth to the initial metastatic cascade in melanoma. Although we have not examined sALCAM expression in human melanoma, it is tempting to speculate that sALCAM may induce the initial step of melanoma metastasis by inhibiting ALCAM-mediated cell adhesion.
Because the amino-terminal Ig domain of ALCAM is the exact adhesive binding site for ALCAM-ALCAM homophilic adhesion, sALCAM is expected to interfere with the aminoterminal Ig domain of ALCAM (20) . sALCAM could partially inhibit the cell aggregation mediated by ALCAM-ALCAM homophilic interaction at 10 g/ml concentration, whereas 1 g/ml sALCAM failed to show such activity. Given that 10 g/ml sALCAM but not 1 g/ml sALCAM demonstrated significant binding to ALCAM, sALCAM may inhibit ALCAM-AL-CAM homophilic interaction via binding to ALCAM competitively. There are several possible explanations for the lack of complete inhibition. First, sALCAM is not able to mask the adhesive capacity of the Ig domain where it binds. Second, the affinity and/or binding capacity of sALCAM to ALCAM is less than that of ALCAM to ALCAM. For cell aggregation mediated by ALCAM homophilic adhesion, clustering of ALCAM through its carboxyl-terminal constant type Ig domains is also essential (20) . Blocking the clustering of ALCAM using an antibody resulted in failure to form cell aggregation although this antibody did not affect the binding capacity of amino-terminal Ig domain. Therefore, it is also possible that sALCAM inhibits ALCAM-ALCAM homophilic interactions through interfering with the function of carboxyl-terminal Ig domains. Further analysis is required to address this issue, including determining which Ig domain function of ALCAM is blocked by sALCAM.
In conclusion, we have isolated a novel soluble isoform of ALCAM. Its ALCAM-dependent and ALCAM-independent effects and differentially regulated transcription suggest that sALCAM is a physiological regulator of endothelial cell function and that sALCAM expands the utility of ALCAM in cellcell and/or cell-extracellular matrix adhesion and communication. We used recombinant sALCAM protein to obtain data presented here. Therefore, detailed analysis of sALCAM including proving its endogenous translation will provide valuable information for a better understanding of ALCAM function.
